Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Short Interest Down 51.6% in June

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the recipient of a significant drop in short interest in the month of June. As of June 15th, there was short interest totalling 283,900 shares, a drop of 51.6% from the May 31st total of 586,700 shares. Based on an average trading volume of 3,880,000 shares, the short-interest ratio is currently 0.1 days.

Sonoma Pharmaceuticals Stock Performance

Shares of Sonoma Pharmaceuticals stock remained flat at $0.21 during trading hours on Friday. The stock had a trading volume of 5,923,486 shares, compared to its average volume of 3,010,728. Sonoma Pharmaceuticals has a 52-week low of $0.12 and a 52-week high of $1.19. The company has a market cap of $4.03 million, a price-to-earnings ratio of -0.30 and a beta of 1.37. The business has a 50 day moving average price of $0.18 and a two-hundred day moving average price of $0.17.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.